On Nov. 16, 2020, Innovation Pharmaceuticals announced that an overseas Clinical Trial Application (CTA) has been submitted to the governing health agency, with a U.S. Investigational New Drug (IND) application also to be submitted this week to the FDA.

Both submissions were part of final preparations for the Companyﾒs multinational Phase 2 clinical trial of Brilacidin for COVID-19, which was on track to commence in 2020 upon gaining required approvals.